Dose-Ranging Effects of Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, as Add-On to Metformin in Subjects With Type 2 Diabetes

Por Rosenstock, Julio, Aggarwal, Naresh, Polidori, David, Zhao, Yue, Arbit, Deborah, Usiskin, Keith, Capuano, George, Canovatchel, William
Publicado em 2012

Evaluation of Bone Mineral Density and Bone Biomarkers in Patients With Type 2 Diabetes Treated With Canagliflozin

Por Bilezikian, John P., Watts, Nelson B., Usiskin, Keith, Polidori, David, Fung, Albert, Sullivan, Daniel, Rosenthal, Norm
Publicado no J Clin Endocrinol Metab (2016)

Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus

Por Watts, Nelson B., Bilezikian, John P., Usiskin, Keith, Edwards, Robert, Desai, Mehul, Law, Gordon, Meininger, Gary
Publicado no J Clin Endocrinol Metab (2016)

Efficacy and safety of canagliflozin compared with placebo in older patients with type 2 diabetes mellitus: a pooled analysis of clinical studies

Por Sinclair, Alan, Bode, Bruce, Harris, Stewart, Vijapurkar, Ujjwala, Mayer, Cristiana, Fung, Albert, Shaw, Wayne, Usiskin, Keith, Desai, Mehul, Meininger, Gary
Publicado em 2014

Effects of canagliflozin on body weight and relationship to HbA(1c) and blood pressure changes in patients with type 2 diabetes

Por Cefalu, William T., Stenlöf, Kaj, Leiter, Lawrence A., Wilding, John P. H., Blonde, Lawrence, Polidori, David, Xie, John, Sullivan, Daniel, Usiskin, Keith, Canovatchel, William, Meininger, Gary
Publicado no Diabetologia (2015)